Market Overview

UPDATE: Oppenheimer Lowers's PT

Related CTRP
Early Global News: Judge Dismisses Yelp Lawsuit, Boston Scientific Recall, Brazil Suing BHP & Vale
Early Global News: Record Online Sales, 400% Jump In Tinder Users, China Experiences Worst Drop In Months
Weekly Recommendation Snapshot TBPH - CYNO - CBM (Marketfy Insights)

According to a research report published this morning, Oppenheimer has lowered's (NASDAQ: CTRP) PT from $34 to $30.

Oppenheimer commented in the report, "CTRP reported 1Q results that were slightly above consensus but roughly in line with our estimates. While 1Q margins came in slightly above our expectations, management suggested margins may contract further in 2Q given its planned coupon program, higher S&M and product development spending. CTRP also guided to 2Q12 revenue growth of 15-20% y/y, implying net revenue of $148-155M, relative to our estimate of $154M and consensus of $157M. We're lowering our earnings estimate to reflect higher expense assumptions while keeping our sales estimates largely unchanged."

Oppenheimer maintains its Outperform rating on, which closed Friday at $18.91.

Latest Ratings for CTRP

Nov 2015Brean CapitalMaintainsBuy
Nov 2015Raymond JamesDowngradesOutperformStrong Buy
Oct 2015OppenheimerMaintainsOutperform

View More Analyst Ratings for CTRP
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Price Target Analyst Ratings


Related Articles (CTRP)

Get Benzinga's Newsletters